factual
Insulin-Intensive Patients Are Dexcom's Core Market
Dexcom's brand targets insulin-intensive diabetics who take basal plus mealtime insulin, about 4 million in the US and 10 million across Dexcom's current markets, while Abbott Libre dominates less intensive type 2 patients because it is cheaper and needs less real-time monitoring.
factualpending
Speaker
AnealEvidence Quote
“There's about 4 million of those patients in the US, 10 million in Dexcom's current markets. And Dexcom is viewed, based on the clinical data, as the most accurate CGM.”
Created: 11/20/2026, 5:18:27 AM
Your notes
Loading notes...